California 2021-2022 Regular Session

California Senate Bill SB987

Introduced
2/14/22  
Introduced
2/14/22  
Refer
2/23/22  
Refer
2/23/22  
Refer
3/30/22  
Refer
3/30/22  
Report Pass
4/21/22  
Refer
4/25/22  
Report Pass
5/19/22  
Engrossed
5/24/22  
Refer
5/27/22  
Refer
5/27/22  
Refer
6/20/22  
Refer
6/20/22  
Report Pass
6/29/22  
Refer
6/30/22  
Refer
6/30/22  
Report Pass
8/11/22  
Report Pass
8/11/22  
Enrolled
8/31/22  
Enrolled
8/31/22  
Chaptered
9/27/22  

Caption

California Cancer Care Equity Act.

Impact

The bill's implementation significantly enhances the ability of low-income individuals to access high-quality cancer care, potentially leading to better treatment outcomes. By ensuring that Medi-Cal managed care plans are connected with accredited treatment centers, patients can benefit from advanced therapies and clinical trials. This initiative is aimed at reducing disparities in cancer treatment that often affect vulnerable populations with a limited range of treatment options.

Summary

Senate Bill 987, also known as the California Cancer Care Equity Act, addresses the need for accessible and effective cancer care for individuals enrolled in the Medi-Cal program. This bill mandates that Medi-Cal managed care plans make a good faith effort to contract with at least one National Cancer Institute (NCI)-designated comprehensive cancer center, affiliated NCORP site, or qualifying academic cancer center within each county. It allows eligible enrollees with complex cancer diagnoses to request referrals to these specialized facilities, thereby ensuring access to necessary treatment options that may not be available through their primary care providers.

Sentiment

The sentiment surrounding SB 987 appears largely positive among healthcare advocates and providers, who view it as a crucial step towards equity in cancer care. Proponents argue that it will facilitate timely and effective treatments for individuals with complex cancer conditions. However, there can be concerns regarding the implementation details, including the definition and periodic review of 'complex cancer diagnoses', as well as ensuring that the capacity and resources of contracting centers can meet the needs of Medi-Cal enrollees.

Contention

Some potential points of contention may arise around the adequacy of efforts made by Medi-Cal managed care plans to fulfill the contracting requirements. Questions may also be raised about the accessibility of out-of-network options should in-network referrals not be successfully established. Additionally, the process by which the Department of Health Care Services defines and updates what constitutes a 'complex cancer diagnosis' could be scrutinized to ensure clear and equitable access for all enrollees.

Companion Bills

No companion bills found.

Similar Bills

CA AB425

Medi-Cal: pharmacogenomic testing.

CA AB1105

Sickle cell disease.

CA SB1267

Clinical laboratories.

CA SB912

Biomarker testing.

CA AB114

Medi-Cal benefits: rapid Whole Genome Sequencing.

MS SB2741

Professional music therapists; provide for licensure by State Department of Health.

CA AB1488

County juvenile transition centers.

MS SB2746

The Mississippi Comprehensive Cancer Care Coalition Task Force; create.